Login
$TVRD
$1.10 -$0.08 (6.78%) Live

$TVRD SEC Filings

Filed On Filing
13 Nov 2026 10-Q
13 Nov 2026 8-K: Results of Operations and Financial Condition

HOUSTON, TX – November 13, 2026 – Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to tre...

14 Aug 2026 10-Q
14 Aug 2026 8-K: Results of Operations and Financial Condition

Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations

30 Jul 2026 8-K: Regulation FD Disclosure

This presentation contains forward - looking statements that involve substantial risks and uncertainties. All statements, other th an statements of historical facts, contained in this presentation, including statements about our expectat...

17 Jul 2026 8-K: Other Events

We have acted as counsel to Tvardi Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the offering by the Company of shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate...

17 Jul 2026 424B5
07 Jul 2026 8-K: Regulation FD Disclosure

This presentation contains forward - looking statements that involve substantial risks and uncertainties. All statements, other th an statements of historical facts, contained in this presentation, including statements about our expectat...

11 Jun 2026 Form 4: Shiff Susan Ph.D., Director

Granted 6,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Smith Cynthia, Director

Granted 6,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Shah Sujal, Director

Granted 6,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Hall Wallace L Jr, Director

Granted 6,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Wyzga Michael S, Director

Granted 6,000 Stock Option (right to buy)

11 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 9, 2026, Tvardi Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the four proposals set forth below. A more detailed des...

13 May 2026 EFFECT
12 May 2026 EFFECT
08 May 2026 POS AM
08 May 2026 CORRESP
08 May 2026 10-Q
08 May 2026 8-K: Results of Operations and Financial Condition

Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support